Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2051
Coca-Cola Consolidated
COKE
$12.8B
| $6.06M | ﹤0.01% |
39,560
-272,652
| -87% | -$40M |
2016 Q3
37 quarters
|
|
|
HAPN
2052
Happen Inc
HAPN
$1.77B
| $6.06M | ﹤0.01% |
319,705
-117,176
| -27% | -$2.07M |
2022 Q1
15 quarters
|
|
2053
Primerica
PRI
$8.48B
| $6.04M | ﹤0.01% |
23,389
-9,045
| -28% | -$2.36M |
2013 Q2
50 quarters
|
|
2054
Privia Health
PRVA
$2.59B
| $6.04M | ﹤0.01% |
254,840
+18,235
| +8% | +$444K |
2022 Q1
15 quarters
|
|
2055
Extreme Networks
EXTR
$3.06B
| $6.04M | ﹤0.01% |
362,884
-28,237
| -7% | -$519K |
2013 Q2
50 quarters
|
|
2056
Chewy
CHWY
$7.3B
| $6.01M | ﹤0.01% |
181,912
-33,721
| -16% | -$1.17M |
2019 Q3
25 quarters
|
|
2057
CALL
Symbotic
SYM
$5.62B
| $6.01M | ﹤0.01% |
101,000
+1,000
| +1% | +$66K |
2025 Q3
1 quarter
|
|
2058
Recursion Pharmaceuticals
RXRX
$2.21B
| $6.01M | ﹤0.01% |
1,469,262
-80,964
| -5% | -$401K |
2022 Q1
15 quarters
|
|
2059
PUT
TransUnion
TRU
$12.2B
| $6M | ﹤0.01% |
70,000
| – | – |
2025 Q2
2 quarters
|
|
2060
Spyre Therapeutics
SYRE
$8.22B
| $5.98M | ﹤0.01% |
182,524
+14,194
| +8% | +$371K |
2023 Q4
8 quarters
|
|
2061
Noble Corp
NE
$6.5B
| $5.98M | ﹤0.01% |
211,728
+28,516
| +16% | +$843K |
2022 Q1
15 quarters
|
|
2062
Fortrea Holdings
FTRE
$1.9B
| $5.98M | ﹤0.01% |
346,443
-4,987
| -1% | -$61.6K |
2023 Q3
9 quarters
|
|
2063
CNA Financial
CNA
$12.5B
| $5.98M | ﹤0.01% |
125,173
+45,068
| +56% | +$2.08M |
2015 Q2
42 quarters
|
|
2064
CALL
Pegasystems
PEGA
$5.58B
| $5.97M | ﹤0.01% |
100,000
| – | – |
2025 Q2
2 quarters
|
|
2065
CALL
Snap
SNAP
$9.44B
| $5.97M | ﹤0.01% |
740,000
| – | – |
2023 Q4
8 quarters
|
|
2066
Cathay General Bancorp
CATY
$4.06B
| $5.97M | ﹤0.01% |
123,298
+22,315
| +22% | +$1.07M |
2013 Q2
50 quarters
|
|
|
SUNC
2067
SunocoCorp LLC
SUNC
$3.91B
| $5.96M | ﹤0.01% |
+120,871
| New | +$6.09M |
2025 Q4
0 quarters
|
|
2068
Legend Biotech
LEGN
$3.61B
| $5.95M | ﹤0.01% |
273,820
+192,748
| +238% | +$5.52M |
2022 Q1
15 quarters
|
|
2069
Magnite
MGNI
$3.55B
| $5.95M | ﹤0.01% |
366,390
+155,735
| +74% | +$2.58M |
2022 Q1
15 quarters
|
|
|
SLDE
2070
Slide Insurance Holdings
SLDE
$2.76B
| $5.94M | ﹤0.01% |
304,978
+267,240
| +708% | +$4.46M |
2025 Q2
2 quarters
|
|
2071
Core & Main
CNM
$7.63B
| $5.94M | ﹤0.01% |
114,234
-52,417
| -31% | -$2.69M |
2022 Q1
15 quarters
|
|
2072
Summit Therapeutics
SMMT
$13.4B
| $5.92M | ﹤0.01% |
338,390
-137,387
| -29% | -$2.58M |
2022 Q1
15 quarters
|
|
2073
CALL
Amprius Technologies
AMPX
$1.41B
| $5.92M | ﹤0.01% |
750,000
| – | – |
2023 Q4
8 quarters
|
|
2074
Korn Ferry
KFY
$4.02B
| $5.91M | ﹤0.01% |
89,488
+12,882
| +17% | +$867K |
2013 Q2
50 quarters
|
|
2075
Immunovant
IMVT
$6.94B
| $5.91M | ﹤0.01% |
232,326
+5,969
| +3% | +$133K |
2023 Q4
8 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.